How artificial intelligence is matching drugs to patients
Observing human brain cells that were raised in a petri dish through a microscope, Dr. Talia Cohen Solal expresses her awe towards the intricate and beautiful nature of the brain.
As a neuroscientist, Dr. Cohen Solal co-founded and currently leads the Israeli health-tech company, Genetika+. Their technology, developed in 2018 offers optimal matching of antidepressants to patients, reducing unwanted side effects and ensuring the effectiveness of the prescribed medication.
Utilising the advancements in stem cell technology, Genetika+ has developed a novel approach in identifying the most appropriate antidepressant for each patient.
With the use of AI software Dr. Talia Cohen Solal explains that their technology can accurately prescribe the right medication on the first attempt.
The process begins with Genetika+ extracting brain cells from a patient's blood sample. These cells are then exposed to various antidepressants and monitored for cellular changes, which are referred to as "biomarkers." Based on the cellular reactions, along with the patient's medical background and genetic information, the AI system can effectively determine the optimal drug to prescribe and the appropriate dosage.
By combining the power of stem cell technology and AI, Genetika+ is paving the way for more effective and personalised treatment for individuals suffering from depressive disorders.
Genetika+ has secured funding from the European Union's European Research Council and European Innovation Council, highlighting how AI is increasingly utilised in the pharmaceutical industry.
In collaboration with pharmaceutical companies, the company is also developing new precision drugs. With over 280 million individuals worldwide experiencing depression according to the World Health Organization, the potential demand for Genetika+'s innovation is significant.
AI Catalog's chief editor
Share on social networks:
